Brought to you by 
GPC AG to buy Mitotix in all-stock deal
Apr 2000
Executive Summary
GPC AG (genomics) is buying Mitotix (cell cycle inhibitors) for 30% of GPC's stock The new company will be called GPC Biotech AG, with GPC AG CEO Bernd Seizinger retaining that role at the new firm; Mitotix's Muzammil Mansuri will lead US operations.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GPC AG to buy Mitotix in all-stock deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice